Literature DB >> 21609022

Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer.

Shawna L Organ1, Jiefei Tong, Paul Taylor, Jonathan R St-Germain, Roya Navab, Michael F Moran, Ming-Sound Tsao.   

Abstract

Colorectal cancer (CRC) is the second leading cause of death from cancer. The MET receptor tyrosine kinase and/or its ligand HGF are frequently amplified or overexpressed in CRC. It is known that tyrosine phosphorylated proteins are involved in progression and metastasis of colorectal cancer; however, little is known about the MET phospho-proteome in CRC. High resolution mass spectrometry was used to characterize immunoaffinity-purified, phosphotyrosine (pY)-containing tryptic peptides of the MET-expressing CRC cell model, DLD1. A total of 266 unambiguously identified pY sites spanning 168 proteins were identified. Quantification of mass spectrometry ion currents identified 161 pY sites, including many not previously linked to MET signaling, that were modulated in abundance by HGF stimulation. Overlay of these data with protein-protein interaction data sets suggested that many of the identified HGF-modulated phospho-proteins may be directly or indirectly associated with MET. Analysis of pY sequence motifs indicated a prevalence of Src family kinase consensus sequences, and reciprocal signaling between Src and MET was confirmed by using selective small molecule inhibitors of these kinases. Therefore, using quantitative phospho-proteomics profiling, kinase modulation by ligand and inhibitors, and data integration, an outline of the MET signaling network was generated for the CRC model.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21609022     DOI: 10.1021/pr200238t

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  8 in total

1.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 2.  Biology of MET: a double life between normal tissue repair and tumor progression.

Authors:  Iacopo Petrini
Journal:  Ann Transl Med       Date:  2015-04

3.  c-MET as a potential therapeutic target and biomarker in cancer.

Authors:  J Rafael Sierra; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

4.  Profiling the dynamics of a human phosphorylome reveals new components in HGF/c-Met signaling.

Authors:  Crystal L Woodard; C Rory Goodwin; Jun Wan; Shuli Xia; Robert Newman; Jianfei Hu; Jin Zhang; S Diane Hayward; Jiang Qian; John Laterra; Heng Zhu
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

Review 5.  Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling.

Authors:  Jin-Ku Lee; Kyeung Min Joo; Jeongwu Lee; Yeup Yoon; Do-Hyun Nam
Journal:  Onco Targets Ther       Date:  2014-10-20       Impact factor: 4.147

6.  Anti-proliferative role of recombinant lethal toxin of Bacillus anthracis on primary mammary ductal carcinoma cells revealing its therapeutic potential.

Authors:  Rekha Khandia; Bramhadev Pattnaik; Katherukamem Rajukumar; Atul Pateriya; Sandeep Bhatia; Harshad Murugkar; Anil Prakash; Hare Krishna Pradhan; Kuldeep Dhama; Ashok Munjal; Sunil K Joshi
Journal:  Oncotarget       Date:  2017-05-30

Review 7.  Colorectal liver metastasis: molecular mechanism and interventional therapy.

Authors:  Hui Zhou; Zhongtao Liu; Yongxiang Wang; Xiaoyong Wen; Eric H Amador; Liqin Yuan; Xin Ran; Li Xiong; Yuping Ran; Wei Chen; Yu Wen
Journal:  Signal Transduct Target Ther       Date:  2022-03-04

8.  p120RasGAP is a mediator of rho pathway activation and tumorigenicity in the DLD1 colorectal cancer cell line.

Authors:  Shawna L Organ; Josephine Hai; Nikolina Radulovich; Christopher B Marshall; Lisa Leung; Takehiko Sasazuki; Senji Shirasawa; Chang-Qi Zhu; Roya Navab; Mitsuhiko Ikura; Ming-Sound Tsao
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.